Primary culture and immortalization of human fallopian tube secretory epithelial cells

Nature Protocols

Volumn 7, Issue 9, 2012, Pages 1755-1764

  Karst, Alison M ^a   Drapkin, Ronny ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CELL ISOLATION; CELL LINE; CELL PROLIFERATION; EPITHELIUM CELL; EXPERIMENTATION; FALLOPIAN TUBE SECRETORY EPITHELIAL CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; UTERINE TUBE DISEASE; UTERINE TUBE MUCOSA; UTERINE TUBE TUMOR;

CELL CULTURE TECHNIQUES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; HUMANS;

EID: 84866087898     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2012.097     Document Type: Article

References (28)

1. Karst, A.M., Levanon, K. & Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. USA 108, 7547-7552 (2011
2. Medeiros, F. et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230-236 (2006 (Pubitemid 43740193)
3. Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26-35 (2007 (Pubitemid 46092026)
4. Crum, C.P. Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol. Oncol. 3, 165-170 (2009
5. Przybycin, C.G., Kurman, R.J., Ronnett, B.M., Shih Ie, M. & Vang, R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am. J. Surg. Pathol. 34, 1407-1416 (2010
6. Crum, C.P. et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19, 3-9 (2007 (Pubitemid 46095865)
7. Kurman, R.J. & Shih Ie, M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum. Pathol. 42, 918-931 (2011
8. Salvador, S. et al. The fallopian tube: Primary site of most pelvic high-grade serous carcinomas. Int. J. Gynecol. Cancer 19, 58-64 (2009
9. Karst, A.M. & Drapkin, R. Ovarian cancer pathogenesis: A model in evolution. J. Oncol. 2010, 932371 (2010
10. Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284-5293 (2008
11. Greene, M.H., Mai, P.L. & Schwartz, P.E. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am. J. Obstet. Gynecol. 204, 19.e1-19.e6 (2011
12. Folkins, A.K., Jarboe, E.A., Roh, M.H. & Crum, C.P. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol. Oncol. 113, 391-396 (2009
13. Levanon, K. et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29, 1103-1113 (2010
14. Fotheringham, S., Levanon, K. & Drapkin, R. Ex vivo culture of primary human fallopian tube epithelial cells. J. Vis. Exp. doi:10.3791/2728 (2011
15. Karst, A.M. & Drapkin, R. The new face of ovarian cancer modeling: Better prospects for detection and treatment. F1000 Med. Rep. 3, 22 (2011
16. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
17. Pearce, C.L. et al. Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium. Br. J. Cancer 100, 412-420 (2009
18. Fasching, P.A. et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol. Oncol. 3, 171-181 (2009
19. Goode, E.L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874-879 (2010
20. Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417-1427 (2009
21. Notaridou, M. et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int. J. Cancer 128, 2063-2074 (2011
22. Bolton, K.L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 42, 880-884 (2010
23. Jazaeri, A.A. et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13, 899-911 (2011
24. Miller, D.G., Adam, M.A. & Miller, A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10, 4239-4242 (1990
25. Kanbe, E. & Zhang, D.E. A simple and quick method to concentrate MSCV retrovirus. Blood Cells Mol. Dis. 33, 64-67 (2004 (Pubitemid 38829600)
26. Laury, A.R. et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am. J. Surg. Pathol. 34, 627-635 (2010
27. Bowen, N.J. et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol. Oncol. 104, 331-337 (2007 (Pubitemid 46135661)
28. Herbert, B.S., Hochreiter, A.E., Wright, W.E. & Shay, J.W. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat. Protoc. 1, 1583-1590 (2006